Search Result

Results for "

Prostate cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PSMA (19) 17β-HSD (2) 5 alpha Reductase (2) Acyltransferase (1) ADC Cytotoxin (1) ADC Linker (3) Adenylate Cyclase (2) Adrenergic Receptor (11) Akt (13) Aldehyde Dehydrogenase (ALDH) (4) Aldose Reductase (6) Amino Acid Derivatives (1) AMPK (4) Androgen Receptor (97) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (4) Apelin Receptor (APJ) (1) Apoptosis (120) Arrestin (1) Atg4 (1) Atg8/LC3 (1) ATM/ATR (1) ATP Synthase (1) Aurora Kinase (1) Autophagy (19) Bacterial (10) Bcl-2 Family (8) Biochemical Assay Reagents (2) Bradykinin Receptor (1) c-Fms (1) c-Kit (1) c-Met/HGFR (1) c-Myc (4) Cannabinoid Receptor (2) Carbonic Anhydrase (1) Carboxypeptidase (1) Caspase (14) Cathepsin (2) CCR (1) CD3 (2) CDK (9) Ceramidase (1) CGRP Receptor (1) Checkpoint Kinase (Chk) (1) Chloride Channel (1) Complement System (1) COX (1) CTLA-4 (1) CXCR (2) Cytochrome P450 (9) Dengue virus (1) DNA Alkylator/Crosslinker (1) DNA-PK (2) DNA/RNA Synthesis (3) Drug Metabolite (5) Drug-Linker Conjugates for ADC (2) DYRK (2) E1/E2/E3 Enzyme (1) EGFR (3) Endogenous Metabolite (14) Endothelin Receptor (1) Epigenetic Reader Domain (28) Estrogen Receptor/ERR (6) Farnesyl Transferase (2) Fatty Acid Synthase (FASN) (8) FGFR (1) Flavivirus (1) Fungal (6) FXR (4) Glucocorticoid Receptor (1) Glucosidase (3) Glutathione Peroxidase (1) Glutathione S-transferase (1) GnRH Receptor (21) GSK-3 (2) HBV (2) HDAC (8) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (3) Histamine Receptor (1) Histone Acetyltransferase (13) Histone Demethylase (12) Histone Methyltransferase (11) HIV (6) HPV (1) HSP (4) HSV (1) IAP (3) ICMT (1) IGF-1R (1) Influenza Virus (4) Insulin Receptor (1) Integrin (2) Interleukin Related (2) IRE1 (1) Isotope-Labeled Compounds (8) JAK (1) Kisspeptin Receptor (3) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (3) Lipoxygenase (4) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) METTL3 (2) MicroRNA (1) Microtubule/Tubulin (10) Mitophagy (1) MMP (3) MNK (1) Monoamine Oxidase (4) mTOR (4) NF-κB (6) Notch (1) Nuclear Factor of activated T Cells (NFAT) (1) Organoid (2) P-glycoprotein (2) p38 MAPK (1) Paraptosis (1) Parasite (3) PARP (11) PD-1/PD-L1 (1) PDK-1 (1) PGE synthase (1) Phosphatase (5) Phospholipase (2) PI3K (6) PIKfyve (1) Pim (4) PKC (2) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (2) Potassium Channel (1) PPAR (5) Progesterone Receptor (6) Prostaglandin Receptor (2) PROTAC Linkers (2) PROTAC-Linker Conjugates for PAC (3) PROTACs (33) Protease Activated Receptor (PAR) (1) Proteasome (1) Pyruvate Kinase (1) Radionuclide-Drug Conjugates (RDCs) (3) Raf (3) RAR/RXR (1) Ras (6) Reactive Oxygen Species (9) Reverse Transcriptase (6) ROR (3) ROS Kinase (1) SARS-CoV (6) SHP2 (3) Sirtuin (3) SOD (1) Src (1) STAT (5) Survivin (1) Telomerase (6) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (7) TRP Channel (4) VD/VDR (1) VEGFR (8) Virus Protease (1) VSV (1) Wnt (2)
By Research Areas:	Cancer (546) Cardiovascular Disease (21) Endocrinology (48) Infection (37) Inflammation/Immunology (41) Metabolic Disease (22) Neurological Disease (8)
Click Chemistry:	Alkynes (4)
Oligonucleotides:	Aptamers (2) Cholesterol (2)

561

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Carlumab CNTO 888	CCR	Cancer
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .

Rosopatamab HUJ-591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

NSC636819	Histone Demethylase	Cancer
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .

Bicalutamide 10+ Cited Publications	Androgen Receptor Autophagy	Cancer
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

AZA1 1 Publications Verification Rac1/Cdc42-IN-1	Ras Apoptosis	Cancer
AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion .

Sipuleucel-T	Phosphatase	Inflammation/Immunology Cancer
Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells .

Spongionellol A	P-glycoprotein	Cancer
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer .

Spongionellol A analog 1	P-glycoprotein	Cancer
Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer .

Avorelin Meterelin; MF 6001	GnRH Receptor	Cancer
Avorelin (Meterelin) is a gonadotropin releasing hormone (GnRH) agonist. Avorelin can be used of the study of prostate cancer .

Neochamaejasmine A	Apoptosis	Cancer
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer .

Bexlosteride LY300502	Others	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .

Astragenol	Others	Inflammation/Immunology Cancer
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research .

Hydroxyflutamide HFT	Androgen Receptor	Cancer
Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC₅₀=700 nM). Hydroxyflutamide can be used for the research of prostate cancer .

BKM-570	Bradykinin Receptor	Cancer
BKM-570 is a nonpeptide bradykinin antagonist with anticancer effects. BKM-570 can be used in the study of lung cancer, prostate cancer and ovarian cancer .

AR Degrader-1	Androgen Receptor	Cancer
AR Degrader-1 is an androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR without obvious cytotoxicity in LNCaP prostate cancer cells .

HYNIC-PSMA	PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research .

Bavdegalutamide 3 Publications Verification ARV-110	Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer .

MIP-1072	PSMA	Cancer
MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an K_i value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .

AKR1C3-IN-13	Ligands for Target Protein for PROTAC Aldose Reductase	Cancer
AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells .

PARP7-IN-16	PARP	Cancer
PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC₅₀s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .

PSMA I&T	PSMA	Cancer
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .

Anticancer agent 253	Apoptosis Akt	Cancer
Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC₅₀s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .

Bicalutamide (Standard)	Androgen Receptor Autophagy	Cancer
Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

MYC-IN-3	c-Myc	Cancer
MYC-IN-3 (compound 37) is a potent MYC inhibitor. MYC-IN-3 shows antiproliferative activity. MYC-IN-3 shows anticancer activity. MYC-IN-3 has the potential for the research of prostate cancer .

Leucinostatin A Antibiotic P168	Fungal Antibiotic	Infection Cancer
Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .

SARD279	Androgen Receptor	Cancer
SARD279 is a potent and selective Androgen Receptor degrader with DC₅₀ value of 1099 nM. SARD279 can be used in prostate cancer research .

Honokiol DCA 1 Publications Verification Honokiol dichloroacetate	Androgen Receptor	Cancer
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .

AKR1C3-IN-10	Aldose Reductase	Cancer
AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC₅₀=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model .

Hydroxyflutamide (Standard)	Androgen Receptor	Cancer
Hydroxyflutamide (Standard) is the analytical standard of Hydroxyflutamide. This product is intended for research and analytical applications. Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC50=700 nM). Hydroxyflutamide can be used for the research of prostate cancer .

TRPM4-IN-2 NBA	TRP Channel	Cancer
TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC₅₀ value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer .

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .

Venuloside A ESK246	Others	Cancer
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

MEB55	Others	Cancer
MEB55 is an antitumor agent. MEB55 shows anti-proliferative activity. MEB55 has the potential for the research of prostate cancer .

Ozarelix D-63153	GnRH Receptor Apoptosis	Cancer
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer .

MnTE-2-PyP chloride BMX-010 chloride	Reactive Oxygen Species	Cancer
MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer .

Androgen receptor antagonist 8	Androgen Receptor	Cancer
Androgen receptor antagonist 8 (Example 13) is an androgen receptor antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC₅₀: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .

Degarelix acetate hydrate FE 200486 acetate hydrate	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate hydrate (FE 200486 acetate hydrate) is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research .

Santalol	Others	Cancer
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer .

Ac-macropa	PSMA	Cancer
Ac-macropa is a PSMA-targeted Actinium-225 Conjugate, and can be used for study of prostate cancer .

WWL0245	Epigenetic Reader Domain	Cancer
WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC₅₀ (<1 nM) than BRD2/3 and PLK1 ( DC₅₀>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4 .

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

Ledoxantrone trihydrochloride CI 958 trihydrochloride	DNA/RNA Synthesis	Cancer
Ledoxantrone (CI 958) trihydrochloride is a DNA helicases inhibitor with an IC₅₀ of 0.17 μM. Ledoxantrone trihydrochloride can be used in the study of prostate cancer .

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

Cat. No.	Product Name

HY-L124

Anti-Prostate Cancer Compound Library

2,449 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2,449 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L107

Anti-Cancer Natural Product Library

1,706 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,706 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

Cat. No.	Product Name	Type

HY-NP017

Prostate specific antigen protein (human) PSA; Native human Prostate specific antigen protein	Native Proteins
Prostate specific antigen protein (human) is a serine protease which produced by prostatic epithelium. Prostate specific antigen protein (human) can be used to study prostatic cancer .

HY-W088413A

DOTA-amide dihydrate	Chelators
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area

HY-P5290

HYNIC-PSMA	PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research .

HY-P0013

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-16168A

Degarelix Maximum Cited Publications 8 Publications Verification FE 200486 free base	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC₅₀ = 3 nM). Degarelix acetate Degarelix acetate (FE 200486) is used for the research of prostate cancer .

HY-106138

Avorelin Meterelin; MF 6001	GnRH Receptor	Cancer
Avorelin (Meterelin) is a gonadotropin releasing hormone (GnRH) agonist. Avorelin can be used of the study of prostate cancer .

HY-16498

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .

HY-16375

Ozarelix D-63153	GnRH Receptor Apoptosis	Cancer
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer .

HY-16168B

Degarelix acetate hydrate FE 200486 acetate hydrate	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate hydrate (FE 200486 acetate hydrate) is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-16168AR

Degarelix (Standard)	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix (Standard) is the analytical standard of Degarelix. This product is intended for research and analytical applications. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research .

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-P5292

HYNIC-iPSMA	PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity .

HY-P5292A

HYNIC-iPSMA TFA	PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity .

HY-P0056

Histrelin	GnRH Receptor	Cancer
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .

HY-P0056A

Histrelin acetate	GnRH Receptor	Cancer
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .

HY-P10422

Multi-Leu peptide ML-peptide, Multi-Leucine (ML)-peptide	Peptides	Cancer
Multi-Leu peptide (ML-peptide) is a potent inhibitor of PACE4 (K_i=22 nM). Multi-Leu peptide can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide can be used to study the specific mechanism of PACE4 in the development of prostate cancer .

HY-P1416

Foxy-5 4 Publications Verification	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA 4 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P2161

TAK-683	Kisspeptin Receptor	Cancer
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P2161B

TAK-683 acetate 1 Publications Verification	Kisspeptin Receptor	Cancer
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P2161A

TAK-683 TFA	Kisspeptin Receptor	Cancer
TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-153550

PSMA-1007	PSMA	Others
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. ¹⁸F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging .

HY-P1813

PSA1 (141-150) PSA-Peptide	Peptides	Cancer
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .

HY-13534

Abarelix 1 Publications Verification R3827; PPI 149	GnRH Receptor	Endocrinology Cancer
Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

HY-13534A

Abarelix Acetate 1 Publications Verification PPI 149 Acetate; R 3827 Acetate	GnRH Receptor	Endocrinology Cancer
Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer research .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613)	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P10511

Pantinin-3	Apoptosis	Infection Cancer
Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .

HY-P4516

Z-Phe-Leu-Glu-pNA	Peptides	Cancer
Z-Phe-Leu-Glu-pNA is a chromogenic substrate for glutamyl endopeptidases. Z-Phe-Leu-Glu-pNA has been used as a synthetic substrate in the study of proteolytic enzymes, including trypsin treatment, subtilisin and chymotrypsin. Z-Phe-Leu-Glu-pNA plays an important role in hormone disorders such as prostate cancer and breast cancer .

HY-P10625

SHLP-6	Apoptosis	Metabolic Disease Cancer
SHLP-6 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP6 increases apoptosis in insulinoma cells NIT1 and human prostate cancer cell 22Rv1. SHLP6 can be used in the study of diabetes and cancer .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors .

HY-P10621

SHLP-1	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
SHLP-1 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-1 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer .

HY-P10624

SHLP-5	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
SHLP-5 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16s ribosomal RNA (MT-RNR2) gene. SHLP-5 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer .

HY-P2284

AD 01	Peptides	Cancer
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner .

HY-P5831

Biotin-H10	Peptides	Cancer
Biotin-H10 is a specific anterior gradient homolog 2 (AGR2) inhibitor with a K_D of 6.4 nM. Biotin-H10 inhibits cancer cells viability .

HY-138951

AY77	Protease Activated Receptor (PAR)	Inflammation/Immunology Cancer
AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC₅₀ of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca ²⁺ release .

HY-P10622

SHLP-3	Apoptosis Reactive Oxygen Species	Metabolic Disease Cancer
SHLP-3 is a mitochondrial derived peptide encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-3 increases cell viability and reduces apoptosis in insulinoma NIT-1β cells and human prostate cancer 22Rv1 cells. SHLP-3 increases mitochondrial function and exerts cytoprotective effects by increasing mitochondrial oxygen consumption rate (OCR), cellular ATP and reducing the ability to produce ROS. SHLP-3 can be used in the study of diabetes and cancer .

HY-P5413

[Lys3]-Bombesin	Peptides	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P10472

Azaline B	GnRH Receptor	Endocrinology
Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC₅₀ of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .

HY-P3668

[D-Lys6]-LH-RH	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist .

HY-P10387

RSM3	METTL3 Apoptosis	Cancer
RSM3, a stapled peptide, is a METTL3-METTL14 inhibitor with an K_d of 3.10 μM. RSM3 inhibits tumor growth while induces cell apoptosis. RSM3 can be used for study of cancer .

HY-P10387A

RSM3 TFA	METTL3 Apoptosis	Cancer
RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an K_d of 3.10 μM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer .

HY-P3118

Bz-IEGR-pNA acetate	Peptides	Others
Bz-IEGR-pNA acetate is a trypsin substrate that can be hydrolyzed by prostate kinase release enzyme-related peptide KLKs .

Cat. No.	Product Name	Target	Research Area

HY-P99188

Carlumab CNTO 888	CCR	Cancer
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .

HY-P99239

Rosopatamab HUJ-591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

HY-P99517

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .

HY-P99189

Cixutumumab IMC-A12; NSC742460	Inhibitory Antibodies	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .

HY-P9992

Pelgifatamab BAY-2315497; PSMA-TTC	Inhibitory Antibodies	Inflammation/Immunology
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of ²²⁵Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

Cat. No.	Product Name	Chemical Structure

HY-N0610AS

Cinnamic acid-d6
Cinnamic acid-d₆ is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-N0610AS2

Cinnamic acid-13C3
Cinnamic acid- ¹³C₃ (3-Phenylacrylic acid- ¹³C₃) is the ¹³C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-70002S1

Enzalutamide-d6
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-14249S1

Bicalutamide-d5
Bicalutamide-d₅ is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-14249S

Bicalutamide-d4
Bicalutamide-d₄ is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

HY-14281S

Trilostane-d3
Trilostane-d₃ is the deuterium-labeled Trilostane (HY-14281). Trilostane-d₃ (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane-d₃ is a synthetic nonhormonal steroid. Trilostane-d₃ can be used for the research of breast cancer and prostate cancer .

HY-111614S

Melengestrol acetate-d6

Melengestrol acetate-d₆ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-111614S1

Melengestrol acetate-d2

Melengestrol acetate-d₂ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-111614S2

Melengestrol acetate-d3

Melengestrol acetate-d₃ is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity[1]. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research[2].

HY-135794S

11-Ketodihydrotestosterone-d3

11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells[1][2].

HY-16474S

Relugolix-d6

Relugolix-d₆ is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81365

	SLC45A3 Antibody (YA1110) PCANAP6; PRST; Slc45a3; Solute carrier family 45 member 3; Prostate cancer-associated protein 6; Prostein	IHC-P	Human
	SLC45A3 Antibody (YA1110) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1110), targeting SLC45A3. SLC45A3 Antibody (YA1110) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-114759

MS-PPOH		Alkynes
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-16247

Apoptone HE3235		Alkynes
Apoptone, synthetic analogue of 3β-androstanediol, is an orally bioavailable anticancer agent. Apoptone is active in rodent models of prostate and breast cancer . Apoptone is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169098

HSP90/LSD1-IN-1		Alkynes
HSP90/LSD1-IN-1 (compound 6) is a HSP90/LSD1 dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

Cat. No.	Product Name		Classification

HY-113289

Brassicasterol		Cholesterol
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

HY-N0171

Beta-Sitosterol (purity>80%) 5+ Cited Publications		Cholesterol
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation .

HY-160046

AS2 sodium		Aptamers
AS2 sodium is an ssDNA aptamer (Kd: 0.7 nM) for prostate-specific antigen (PSA). AS2 sodium does not bind non-specifically to the anti-target and has the potential to be used in diagnostic systems for prostate cancer detection .

HY-147081

AS 1411 AGRO-100		Aptamers
AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Prostate cancer

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products